The mds Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mds Hub cannot guarantee the accuracy of translated content. The mds and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mds content recommended for you
Theo de WitteDuring the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the MDS Hub was pleased to speak to Theo de Witte, Radboud University Medical Center, Nijmegen, NL. We asked, Is there confusion between the World Health Organisation (WHO) and Molecular International Prognostic Scoring System (IPSS-M) classifications of myelodysplastic syndromes (MDS)?
Is there confusion between WHO and IPSS-M classifications of MDS?
De Witte begins by discussing the basis of the current IPSS-M criteria on cytogenetics characteristics, blast percentage, and severity of cytopenia, despite half of patients diagnosed with MDS having normal karyotypes. Moving on, De Witte compares the IPSS-M with the recently updated WHO classification and its focus on diagnosis and morphological features. De Witte emphasizes the importance of identifying specific genetic mutations to determine prognosis more accurately, omitted from the WHO classification.
